Leerink Partners analyst Puneet Souda maintained a Buy rating on Bio-Techne (NASDAQ:TECH) Corporation on Wednesday, setting a price target of $285, which is approximately 2.20% above the present share price of $278.87.
Souda expects Bio-Techne Corporation to post earnings per share (EPS) of $0.95 for the third quarter of 2020.
The current consensus among 7 TipRanks analysts is for a Moderate Buy rating of shares in Bio-Techne, with an average price target of $287.67.
The analysts price targets range from a high of $328 to a low of $260.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $194.68 million and a net profit of $47.79 million. The company's market cap is $10.58 billion.
According to TipRanks.com, Leerink Partners analyst Puneet Souda is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 27.7% and a 72.15% success rate.
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Biotechnology, Protein Platforms, Diagnostics, and Corporate. The Biotechnology segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and related reagents, as well as in situ hybridization, media and other cell culture products and reagents to the biotechnology research community. The Protein Platforms segment develops, manufactures, and sells tools to simplify protein analysis. The Diagnostics segment includes blood chemistry and blood gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market worldwide. The company was founded on 1976 and is headquartered in Minneapolis, MN.